SARS-CoV-2-Specific Adaptive Immunity in COVID-19 Survivors With Asthma

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Aug 4

PMID 35924252

Authors

Li Chen

Junqing Yue

Shengding Zhang

Wenxue Bai

Lu Qin

Cong Zhang

Bihao Wu

Moxuan Li

Shuyun Xu

Qing Jiang

Lin Yang

Qingxiu Xu

Rongfei Zhu

Min Xie

Rui Gong

Affiliations

Soon will be listed here.

Abstract

Background: Asthma patients potentially have impaired adaptive immunity to virus infection. The levels of SARS-CoV-2-specific adaptive immunity between COVID-19 survivors with and without asthma are presently unclear.

Methods: COVID-19 survivors (patients with asthma n=11, with allergies n=8, and COVID-19 only n=17) and non-COVID-19 individuals (asthmatic patients n=10 and healthy controls n=9) were included. The COVID-19 patients were followed up at about 8 months and 16 months after discharge. The clinical characteristics, lymphocyte subsets, memory T cells, and humoral immunity including SARS-CoV-2 specific antibodies, SARS-CoV-2 pseudotyped virus neutralization assay, and memory B cells were analyzed in these subjects.

Results: The strength of virus-specific T cell response in COVID-19 survivors was positively correlated with the percentage of blood eosinophils and Treg cells (r=0.4007, p=0.0188; and r=0.4435, p=0.0086 respectively) at 8-month follow-up. There were no statistical differences in the levels of SARS-CoV-2-specific T cell response between the COVID-19 survivors with, and without, asthma. Compared to those without asthma, the COVID-19 with asthma survivors had higher levels of SARS-CoV-2-specific neutralizing antibodies (NAbs) at the 8-month follow-up (p<0.05). Moreover, the level of NAbs in COVID-19 survivors was positively correlated with the percentage of Treg and cTfh2 cells (r=0.5037, p=0.002; and r=0.4846, p=0.0141), and negatively correlated with the percentage of Th1 and Th17 cells (r=-0.5701, p=0.0003; and r=-0.3656, p=0.0308), the ratio of Th1/Th2, Th17/Treg, and cTfh1/cTfh2 cell (r=-0.5356, r=-0.5947, r=-0.4485; all p<0.05). The decay rate of NAbs in the COVID-19 survivors with asthma was not significantly different from that of those without asthma at 16-month follow-up.

Conclusion: The level of SARS-CoV-2-specific NAbs in COVID-19 survivors with asthma was higher than that of those without asthma at 8-month follow-up. The SARS-CoV-2-specific T cell immunity was associated with blood eosinophils and Treg percentages. The SARS-CoV-2-specific humoral immunity was closely associated with cTfh2/cTfh1 imbalance and Treg/Th17 ratio. According to the findings, asthmatic patients in COVID-19 convalescent period may benefit from an enhanced specific humoral immunity, which associates with skewed Th2/Th1 and Treg/Th17 immune.

Citing Articles

Altered COVID-19 immunity in children with asthma by atopic status.

Tong S, Scott J, Eyoh E, Werthmann D, Stone A, Murrell A J Allergy Clin Immunol Glob. 2024; 3(2):100236.

PMID: 38590754 PMC: 11000189. DOI: 10.1016/j.jacig.2024.100236.

Mucosal Immunity against SARS-CoV-2 in the Respiratory Tract.

Noh H, Rha M Pathogens. 2024; 13(2).

PMID: 38392851 PMC: 10892713. DOI: 10.3390/pathogens13020113.

References

Kuo C, Pavlidis S, Loza M, Baribaud F, Rowe A, Pandis I . T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED. Eur Respir J. 2017; 49(2). DOI: 10.1183/13993003.02135-2016. View

Stephens D, McElrath M . COVID-19 and the Path to Immunity. JAMA. 2020; 324(13):1279-1281. DOI: 10.1001/jama.2020.16656. View

Simpson J, Carroll M, Yang I, Reynolds P, Hodge S, James A . Reduced Antiviral Interferon Production in Poorly Controlled Asthma Is Associated With Neutrophilic Inflammation and High-Dose Inhaled Corticosteroids. Chest. 2016; 149(3):704-13. DOI: 10.1016/j.chest.2015.12.018. View

Rockstroh A, Wolf J, Fertey J, Kalbitz S, Schroth S, Lubbert C . Correlation of humoral immune responses to different SARS-CoV-2 antigens with virus neutralizing antibodies and symptomatic severity in a German COVID-19 cohort. Emerg Microbes Infect. 2021; 10(1):774-781. PMC: 8079054. DOI: 10.1080/22221751.2021.1913973. View

Wirsum C, Glaser C, Gutenberger S, Keller B, Unger S, Voll R . Secondary Antibody Deficiency in Glucocorticoid Therapy Clearly Differs from Primary Antibody Deficiency. J Clin Immunol. 2016; 36(4):406-12. DOI: 10.1007/s10875-016-0264-7. View

Kaiko G, Horvat J, Beagley K, Hansbro P . Immunological decision-making: how does the immune system decide to mount a helper T-cell response?. Immunology. 2007; 123(3):326-38. PMC: 2433332. DOI: 10.1111/j.1365-2567.2007.02719.x. View

Eggert L, He Z, Collins W, Lee A, Dhondalay G, Jiang S . Asthma phenotypes, associated comorbidities, and long-term symptoms in COVID-19. Allergy. 2021; 77(1):173-185. PMC: 8222896. DOI: 10.1111/all.14972. View

Vignali D, Collison L, Workman C . How regulatory T cells work. Nat Rev Immunol. 2008; 8(7):523-32. PMC: 2665249. DOI: 10.1038/nri2343. View

Josefowicz S, Lu L, Rudensky A . Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012; 30:531-64. PMC: 6066374. DOI: 10.1146/annurev.immunol.25.022106.141623. View

10.

Davoine F, Cao M, Wu Y, Ajamian F, Ilarraza R, Kokaji A . Virus-induced eosinophil mediator release requires antigen-presenting and CD4+ T cells. J Allergy Clin Immunol. 2008; 122(1):69-77, 77.e1-2. DOI: 10.1016/j.jaci.2008.03.028. View

11.

Sette A, Crotty S . Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021; 184(4):861-880. PMC: 7803150. DOI: 10.1016/j.cell.2021.01.007. View

12.

Huang B, Chen Z, Sidell M, Eckel S, Martinez M, Lurmann F . Asthma Disease Status, COPD, and COVID-19 Severity in a Large Multiethnic Population. J Allergy Clin Immunol Pract. 2021; 9(10):3621-3628.e2. PMC: 8353223. DOI: 10.1016/j.jaip.2021.07.030. View

13.

Grandbastien M, Piotin A, Godet J, Abessolo-Amougou I, Ederle C, Enache I . SARS-CoV-2 Pneumonia in Hospitalized Asthmatic Patients Did Not Induce Severe Exacerbation. J Allergy Clin Immunol Pract. 2020; 8(8):2600-2607. PMC: 7320869. DOI: 10.1016/j.jaip.2020.06.032. View

14.

Wark P, Pathinayake P, Kaiko G, Nichol K, Ali A, Chen L . ACE2 expression is elevated in airway epithelial cells from older and male healthy individuals but reduced in asthma. Respirology. 2021; 26(5):442-451. PMC: 8014151. DOI: 10.1111/resp.14003. View

15.

Sunjaya A, Allida S, Di Tanna G, Jenkins C . Asthma and COVID-19 risk: a systematic review and meta-analysis. Eur Respir J. 2021; 59(3). PMC: 8361304. DOI: 10.1183/13993003.01209-2021. View

16.

Samarasinghe A, Melo R, Duan S, LeMessurier K, Liedmann S, Surman S . Eosinophils Promote Antiviral Immunity in Mice Infected with Influenza A Virus. J Immunol. 2017; 198(8):3214-3226. PMC: 5384374. DOI: 10.4049/jimmunol.1600787. View

17.

Yang J, Koh H, Moon S, Yoo I, Ha E, You S . Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study. J Allergy Clin Immunol. 2020; 146(4):790-798. PMC: 7428784. DOI: 10.1016/j.jaci.2020.08.008. View

18.

Grifoni A, Weiskopf D, Ramirez S, Mateus J, Dan J, Rydyznski Moderbacher C . Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020; 181(7):1489-1501.e15. PMC: 7237901. DOI: 10.1016/j.cell.2020.05.015. View

19.

Wang M, Zhang N, Zheng M, Li Y, Meng L, Ruan Y . Cross-talk between T2 and T17 pathways in patients with chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2019; 144(5):1254-1264. DOI: 10.1016/j.jaci.2019.06.023. View

20.

Rosenberg H, Dyer K, Domachowske J . Respiratory viruses and eosinophils: exploring the connections. Antiviral Res. 2009; 83(1):1-9. PMC: 2741084. DOI: 10.1016/j.antiviral.2009.04.005. View